Tag: healthcare

Oncotarget News

Oncotarget

<img width="300" height="100" src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image" alt="Oncotarget" decoding="async" srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" sizes="(max-width: 300px) 100vw, 300px" />

Balancing Time, Cost, and Quality in Cardio-Oncology Care

June 13, 2025

The unattainable triangle, also known as the iron triangle or triple constraint, traditionally applied in business as a model for balancing time, cost, and quality, offers valuable insight into the... read more

Oncotarget

<img width="300" height="100" src="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png" class="alignleft blogfeed wp-post-image" alt="Oncotarget" decoding="async" srcset="https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-300x100.png 300w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1024x341.png 1024w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-768x256.png 768w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1-1200x400.png 1200w, https://www.oncotarget.net/wp-content/uploads/2022/06/Oncotarget_Linkedin-Header-Image-1.png 1500w" sizes="(max-width: 300px) 100vw, 300px" />

Pitfalls of FDA-Approved Germline Cancer Predisposition Tests

December 30, 2024

The FDA approval on September 29, 2023, for 'class III de novo' blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct... read more